Sun, Xueqin http://orcid.org/0000-0003-3970-9909
Klingbeil, Olaf
Lu, Bin
Wu, Caizhi http://orcid.org/0000-0002-2449-2818
Ballon, Carlos
Ouyang, Meng
Wu, Xiaoli S.
Jin, Ying
Hwangbo, Yon
Huang, Yu-Han
Somerville, Tim D. D.
Chang, Kenneth
Park, Jung
Chung, Taemoon http://orcid.org/0000-0003-2463-5310
Lyons, Scott K.
Shi, Junwei http://orcid.org/0000-0002-8427-6316
Vogel, Hannes
Schulder, Michael
Vakoc, Christopher R. http://orcid.org/0000-0002-1158-7180
Mills, Alea A. http://orcid.org/0000-0003-4416-6646
Article History
Received: 25 September 2020
Accepted: 10 November 2022
First Online: 21 December 2022
Competing interests
: C.R.V. has received consulting fees from Flare Therapeutics, Roivant Sciences and C4 Therapeutics, has served on the advisory boards of KSQ Therapeutics, Syros Pharmaceuticals and Treeline Biosciences, has received research funding from Boehringer–Ingelheim and Treeline Biosciences, and owns a stock option from Treeline Biosciences.